Sterol carrier protein (SCP) is a highly abundant, ubiquitous, low molecular weight protein that has a rapid turnover and multifunctional roles in lipid metabolism and transport. It is also known as the fatty acid-binding protein.
These and other characteristics led to studies on the possible role of SCP in mediation of steroidogenic responses of the adrenal gland to corticotropin. To quantitate the level of SCP in adrenal tissue and subcellular fractions, a specific immunochemical assay was developed using an antibody to homogeneous liver SCP. SCP is a major protein in adrenal cells (>100 ugi/mg of total protein). The bulk of it is present in the soluble (60%) and mitochondrial (35%) fractions. Nearly all mito- chondrial SCP is present in the inner membrane. Adrenal SCP undergoes a dramatic diurnal variation, varying from 2% to 12% of total protein. When corticotropin was administered in vivo in the presence of aminoglutethimide, an inhibitor of steroidogenesis, there was a parallel movement of SCP with cholesterol to the inner mitochondrial membrane. Other work showed mitochondrial SCP levels increase only in situations where there is an increase in cholesterol levels. These findings strongly suggest that one of the functions of adrenal SCP is to participate in the corticotropin-stimulated movement of cholesterol to the inner mitochondrial membrane for steroidogenesis.
It is well known that steroidogenesis in adrenal cortical tissue is stimulated by corticotropin (ACTH) and that the ratelimiting step is conversion of cholesterol to pregnenolone (e.g., see ref. 1) . The latter reaction is catalyzed by a cytochrome P-450 cholesterol-side-chain-cleavage (CSCC) system located in the inner mitochondrial membrane (2, 3) . Studies from numerous laboratories indicate that enhanced transport of cholesterol to the cytochrome P-450 CSCC system accounts, at least in part, for the increase in steroid synthesis in response to ACTH (e.g., see refs. 4-7). Related observations are that inhibitors of protein synthesis decrease association of cholesterol with the active site of the cytochrome P-450 CSCC system and block movement of cholesteroi from outer to inner mitochondrial membranes (8) (9) (10) .
These findings suggest an ACTH-regulated protein may be involved in adrenal cholesterol movements. In this regard, some of us previously purified from liver a highly abundant, ubiquitous, low molecular weight protein that has a short half-life and multifunctional roles in lipid metabolism and transport (11) (12) (13) . This protein was originally called squalene and sterol carrier protein (SCP) (11, 14) . It is structurally identical to a protein called fatty acid-binding protein (e.g., see refs. 11, 15, and 16) . The specific requirement for SCP in cholesterol synthesis and metabolism (11, 17) , its ability to bind sterols and fatty acids (15, 18) , its participation in fatty acid transport and metabolism (12, 15) , its abundance in tissues exhibiting rapid lipid turnover [i.e., liver, intestine, ovary, and adrenal (19) ], and especially its activation of pregnenolone production by adrenal mitochondria (20, 21) -suggest that SCP plays an important role in stimulation of steroidogenesis in the adrenal by ACTH.
In this report we describe the subcellular distribution of adrenal SCP, its remarkable turnover and diurnal variation, and its movement with cholesterol to the inner mitochondrial membrane in response to ACTH stimulation.
EXPERIMENTAL PROCEDURES
Materials. ACTH was obtained from Armour Pharmaceutical (Phoenix, AZ). Aminoglutethimide was a gift from CIBA Pharmaceutical. Male and female Sprague-Dawley rats were obtained from Bio-Lab (St. Paul, MN), and male hypophysectomized Sprague-Dawley rats were from Hormone Assay Laboratories (Chicago, IL).
Methods. Diurnal variation studies. Twenty-four female rats (175-200 g) were maintained for 1 week on a 12-hr alternating light/dark cycle. They were allowed free access to Purina Rat Chow and water. At 3-hr intervals over a 24-hr period, three animals were killed by decapitation. The adrenals were removed, decapsulated, and homogenized in 0.25 M sucrose buffered with 3 mM Tris HCl (pH 7.4) (buffered sucrose). SCP levels were quantitated by immunoprecipitation.
Stimulation with ACTH in vivo. Eighteen male hypophysectomized rats (175-200 g) were maintained for 48 hr after hypophysectomy. Then the animals were divided into three experimental groups (control, ACTH, and ACTH plus aminoglutethimide), with six animals in each group. ACTH (2 units per animal) and aminoglutethimide (10 mg/100 g of body weight) were administered intraperitoneally in saline 1 hr and 2 hr, respectively, prior to stunning and decapitation.
The adrenal glands were rapidly removed, decapsulated, and homogenized in buffered sucrose for subcellular fractionation.
Stimulation with ACTH in vitro. Male rats (175-200 g)
were maintained for 1 week on a 12-hr alternating light/dark cycle. They were killed 3 hr into the light cycle by stunning and decapitation. The adrenal glands were rapidly removed, decapsulated, and quartered. They were incubated (8 glands per ml) in Krebs-Ringer bicarbonate buffer containing glucose (2 mg/ml) under 95% 02/5% CO2 at 370C for 20 min.
Then, the adrenals were placed in fresh buffer, and incubations were continued with ACTH (400 milliunits/ml) for 45 min or with aminoglutethimide (0.76 mM) for 30 min, followed by addition of ACTH and incubation for 45 min. Mitochondria were prepared after homogenization of the adrenals in buffered sucrose. Subcellular fractionation of adrenal homogenates. Subcellular fractions of adrenal homogenates were prepared by differential centrifugation (22) . Mitochondria were purified Abbreviations: SCP, squalene and sterol carrier protein; ACTH, corticotropin; CSCC, cholesterol side-chain cleavage.
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by density gradient centrifugation and characterized by using enzyme markers (22) ; they were subfractionated by the digitonin method of Greenawalt (23) . Identical conditions of homogenization and isolation were used in all experiments to insure consistent, reproducible values for distribution of cholesterol and SCP.
Assay of adrenal SCP by immunoprecipitation. Rabbits were immunized with homogeneous rat liver SCP. The IgG fraction of the immune serum was purified by using a protein A affinity column (24) . The monospecificity of the anti-SCP IgG was confirmed by immunoelectrophoresis and immunodiffusion (25) (see Fig. 1 ). Adrenal homogenates and subcellular fractions (except the soluble fraction) were sonicated for 30 sec, followed by complete solubilization with an equal volume of 1% Triton X-100 at 250C for 15 min. Immunoprecipitation of the homogenate and subcellular fractions was carried out as follows (26) Protein and cholesterol analyses. Protein concentration was determined by a modification of the Lowry procedure (27). Samples for cholesterol analysis were extracted by the method of Folch et al. (28) . Cholesterol was quantitated by using a Hewlett-Packard 5700 A gas chromatograph with a dual hydrogen flame ionization detector and 5708 integrator. The flow rates of hydrogen and air were 50 and 300 ml/min, respectively. The column (Hewlett-Packard) was 6 ft x 0.25 in (o.d.) (1.83 m x 6.4 mm); it was silanized and prepacked with 3% (wt/vol) SP2100 on Chromosorb W-HP, 80-100 mesh. Column and detector temperatures were 270°C and 300°C, respectively. Nitrogen, at a flow rate of 50 ml/mim, was used as carrier gas. Sample size was 0.5 ,Al. Cholesterol levels were determined from a standard curve.
RESULTS
Subcellular Distribution of Adrenal SCP. The level and distribution of SCP in adrenal homogenates and the four major subcellular fractions were quantitated by immunoprecipitation with a purified antibody to homogeneous rat liver SCP (11) . As shown in Table 1 , SCP is a major protein in adrenal cells (>100 ,ug/mg of total protein); the bulk of it was present in the soluble (60%) and mitochondrial (35%) fractions, with lower levels in the nuclear (4%) and microsomal fractions (1%). To verify these findings, the immunoprecipitates of the soluble and mitochondrial fractions were subjected to NaDodSO4 gel electrophoresis. Their gel scans (Fig. 1, traces B and C) exhibited the two expected IgG peaks (Fig. 1, trace A) and a single peak with the mobility of liver SCP (Fig. 1, trace D) . To determine the location of adrenal mitochondrial SCP, purified mitochondria (22) were subfractionated (23) . For unstimulated hypophysectomized rats, 85% of mitochondrial SCP was associated with the inner membrane, and the remainder was distributed in the matrix and intermembrane medium ( Table 2 ). Less than 2% of mitochondrial SCP was associated with the outer membrane.
Diurnal Variation of Adrenal SCP. The data in Fig. 2 demonstrate that rat adrenal SCP undergoes a dramatic diurnal variation in amount, similar to that occurring in liver (12, 13). During a 12-hr dark/12-hr light cycle, the adrenal exhibited a biphasic pattern in SCP level. A 6-fold increase in SCP occurred during the dark period, peaking at the mid-point (Fig.  2) . During the first 6 hr of the dark period, the level of SCP increased from 2% to 12% of total adrenal protein and then appeared to be degraded rapidly, indicating fast turnover of adrenal SCP.
Effect of ACTH on Adrenal SCP and Cholesterol Levels. We previously have suggested that SCP regulates lipid metabolism through changes in its cellular level (12, 13) . The remarkable diurnal variation in adrenal SCP level (Fig. 2) suggests a similar role for SCP in the adrenal, where lipid metabolism is specialized toward synthesis of steroid hormones. Since ACTH is the major stimulator of steroid hormone production in the adrenal, we examined the influence of ACTH on the level and distribution of SCP in the adrenal under conditions known to alter the level and distribution of cholesterol (6) . Experiments were performed in hypophysectomized rats to accentuate effects of externally administered ACTH. Aminoglutethimide, an inhibitor of steroid hormone Adrenal mitochondrial cholesterol and SCP levels in each of the experimental animal groups (Fig. 3B ) displayed patterns that were largely similar to those seen with homogenates (Fig. 3A) . Treatment of animals with ACTH alone did cause a small increase in mitochondrial cholesterol levels (from 15.5 pAg/mg of protein in controls to 19.0 .&g/mg of protein in stimulated animals) with no change in SCP levels. Also, the increases in mitochondrial cholesterol and SCP levels caused by ACTH in the presence of aminoglutethimide were accentuated in comparison to homogenate values.
In order to determine the location of SCP within adrenal mitochondria of the ACTH-treated animals, purified mitochondria were subfractionated (Table 2) the inner membrane; in the presence of both ACTH and aminoglutethimide, nearly all (94%) was associated with the inner membrane. The concentrations of both cholesterol and SCP in inner mitochondrial membrane fractions isolated from each of the experimental animal groups are shown in Fig. 3C . In comparison to control membrane levels, treatment with ACTH alone altered neither cholesterol nor SCP levels in inner membranes. In contrast, treatment with ACTH in the presence of aminoglutethimide resulted in a marked accumulation relative to control membranes of both cholesterol (from 15.6 to 29.5 pg/mg of protein) and SCP (from 43.9 to 59.5 ug/mg of protein)-an approximate net increase of 33 mol of cholesterol and 1 mol of SCP.
The experiments in vivo just described were next carried out on adrenal tissue in vitro. Adrenals were incubated in buffer alone or with ACTH or with aminoglutethimide followed by ACTH. Mitochondria were isolated and analyzed for cholesterol and SCP content as described for the studies in vivo. Stimulation of adrenals with ACTH did not alter the mitochondrial cholesterol and SCP levels, similar to findings in vivo (Fig., 3B) . In contrast to the studies in vivo, in the presence of both ACTH and aminoglutethimide there was a small, barely significant, accumulation of cholesterol and no accumulation of SCP. The increase in cholesterol level caused by ACTH and aminoglutethimide was a fraction of that occurring in vivo (Fig. 3B) , an observation in accord with reports of previous workers (31) . Thus, in the absence of an external source of cholesterol (i.e., serum lipoproteins; cf. ref. 32) , there is little movement of cholesterol to adrenal mitochondria and no detectable movement of SCP.
DISCUSSION
The results presented here and our previous findings (20, 21) strongly suggest that one of the functions of adrenal SCP is to participate in the ACTH-stimulated movement of cholesterol to the inner mitochondrial membrane for steroidogenesis. The data for cholesterol are also in accord with the report of Privalle et at. (6) that ether stress stimulates movement of cholesterol to the inner membranes of adrenal mitochondria. The ACTH-stimulated movements in vivo of both cholesterol and SCP to the inner mitochondrial membrane were detected only in the presence of an inhibitor of steroid hormone production (6, 29, 30) . This finding indicates that with ACTH and in -the absence of the inhibitor there is turnover, or recycling, or excretion of SCP, while cholesterol is converted to pregnenolone by the cytochrome P450 CSCC system. These studies do not address the question of whether changes in cholesterol and SCP levels occur simultaneously-i.e., with the same time course. The occurrence and accumulation of SCP in the inner mitochondrial membrane do imply that SCP [Mr 14J;84 (16) Other striking characteristics of adrenal SCP are its remarkable abundance, diurnal variation, and turnover-again suggesting a role for SCP in regulating metabolic responses to ACTH stimulation. These responses could involve changes in fatty acid and other lipid synthesis, metabolism, and transport, as well as steroid hormone production from cholesterol.
Several proteins in addition to SCP (20, 21) were recently reported to stimulate pregnenolone production by adrenal mitochondria (10, 35, 36) . All are cytosolic proteins. One (Mr 2,200) may be an active fragment of adrenal SCP, as suggested by Pedersen and Brownie (10) . Another is a liver protein, apparently distinct from SCP and much less abundant than SCP (35, 37) . The latter protein was detected in the adrenal cytosol but was not characterized (38) 
